DSM-Firmenich AG

Chart & Performance

D1W1MN

P/E

—

P/S

0.25

EPS

—

Div Yield, %

21.40%

Shrs. gr., 5y

5.75%

Rev. gr., 5y

2.78%

Revenues

10.63b

+26.66%

Net income

-652m

CFO

1.27b

+37.05%

Earnings

Feb 13, 2025

Profile

DSM-Firmenich AG, a science-based company, engages in beauty, health, and nutrition businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Perfumery & Beauty; Animal Nutrition & Health (ANH); Health, Nutrition & Care (HNC); and Food & Beverage segments. The Perfumery & Beauty offers perfumery and aroma ingredients. The Animal Nutrition & Health segment offers essential products, including vitamins, premixes, and carotenoids; performance solutions, such as enzymes, microbes, and eubiotics; precision services comprising support with data analysis to measure animal health and environmental footprint on farm level and feed safety; and methane reducing feed additive for ruminants. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, personal care and aroma, and biomedical materials markets. It offers vitamins, nutritional lipids, minerals, carotenoids, nutraceuticals, digestive enzymes, probiotics and prebiotics, active pharmaceutical ingredients, and sunscreen filters, as well as a range of biomedical solutions; premix, market-ready solutions, and personalized nutrition solutions; and regulatory affairs and formulation expertise, and customized solutions. The Food & Beverage segment provides ingredients and solutions for use in a range of food products, such as dairy; bakery, cereals, and bars; savory food; beverages and brewing; confectionery and fruit; plant-based meat and fish alternatives; and petfood. The company was founded in 1902 and is headquartered in Kaiseraugst, Switzerland.

URL

https://www.dsm-firmenich.com

IPO date

Apr 18, 2023

Employees

29,306

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	10,627,000 26.66%	8,390,000 -26.69%	11,444,000 41.18%
Cost of revenue	11,195,000	7,673,000	10,693,000
Unusual Expense (Income)
NOPBT	(568,000)	717,000	751,000
NOPBT Margin		8.55%	6.56%
Operating Taxes	(18,000)	124,000	115,000
Tax Rate		17.29%	15.31%
NOPAT	(550,000)	593,000	636,000
Net income	(652,000) -241.74%	460,000 -47.25%	872,000 94.64%
Dividends	(582,000)	(345,000)	(266,000)
Dividend yield	2.71%
Proceeds from repurchase of equity	501,000	(160,000)	(165,000)
BB yield	-2.34%
Debt
Debt current	716,000	86,000	55,000
Long-term debt	4,529,000	2,978,000	3,197,000
Deferred revenue	70,000	25,000
Other long-term liabilities	746,000	601,000	1,198,000
Net debt	1,815,000	(254,000)	943,000
Cash flow
Cash from operating activities	1,265,000	923,000	1,427,000
CAPEX	(555,000)	(644,000)	(433,000)
Cash from investing activities	(795,000)	871,000	208,000
Cash from financing activities	(820,000)	(598,000)	(984,000)
FCF	(2,402,000)	(90,000)	1,062,000
Balance
Cash	2,563,000	2,880,000	2,050,000
Long term investments	867,000	438,000	259,000
Excess cash	2,898,650	2,898,500	1,736,800
Stockholders' equity	11,383,000	10,570,000	9,103,000
Invested Capital	25,817,350	11,492,500	11,908,200
ROIC		5.07%	5.47%
ROCE		4.76%	5.50%
EV
Common stock shares outstanding	233,200	173,300	173,056
Price	92.00
Market cap	21,454,400
EV	23,431,400
EBITDA	739,000	1,369,000	1,397,000
EV/EBITDA	31.71
Interest	166,000	70,000	214,000
Interest/NOPBT		9.76%	28.50%